IDEAYA Biosciences (IDYA) AI Stock Analysis

• Market Cap: $1.94B
• Dividend Yield: N/A
• Average Volume (3M): 1.18M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.48
• Revenue Growth: -54.85%
• EPS Growth: -79.25%
• Country: US
• Employees: 131
• Sector: Healthcare
• Sector Strength: 39
• Industry: Biotechnology
• EPS (TTM): -0.82
• Shares Outstanding: 87,581,960
• 10 Day Avg. Volume: 1,107,220
• 30 Day Avg. Volume: 1,175,442
• PEG Ratio: 6.18
• Price to Book (P/B): 2.15
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -8.31
• Enterprise Value/Market Cap: 0.36
• Enterprise Value/Revenue: 23.02
• Enterprise Value/Gross Profit: 130.78
• Enterprise Value/Ebitda: -0.63
• 1Y Price Target: $50.89
• Price Target Upside: 130.27% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 9

• Rating: 53 Neutral
• Price Target: $22.00 ▼(-0.45%Downside)

The overall stock score of 53 reflects significant financial performance challenges, as evidenced by declining revenues and net losses, despite a strong equity position. Technical analysis shows moderate positive momentum, but valuation is unattractive due to negative profitability. Without earnings call data or impactful corporate events, these factors dominate the assessment.

Positive Factors

Clinical Trial Outcomes

Data for the daro+crizo combination so far look superior to the standard of care.

Market Opportunities

Registry data suggest that the market opportunity for HLA-negative could be 3-4 times relative to HLA-positive, indicating a potentially larger market than previously expected.

Pipeline Updates

The company's updates from its early pipeline should offer upside in the next 12-18 months.

Negative Factors

Approval Challenges

An accelerated approval opportunity, which the company previously highlighted as a possibility, is unlikely.

Investor Concerns

Investor focus on OS is unlikely to be fully addressed at the upcoming disclosure.

Market Uncertainty

Investors are understandably cautious on the de-risking potential of progression-free survival data on the overall survival full approval endpoint, indicating some uncertainty in the market.

IDEAYA Biosciences Business Overview & Revenue Model

Company Description

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

How the Company Makes Money

IDEAYA Biosciences generates revenue primarily through collaboration and license agreements with other pharmaceutical and biotechnology companies. These partnerships typically involve upfront payments, milestone payments, and royalties on sales if the partnered drugs successfully reach the market. For instance, IDEAYA may collaborate with larger pharmaceutical companies to co-develop and commercialize its drug candidates, leveraging their partner's resources and expertise in exchange for shared financial benefits. The company's revenue is also supported by research grants and funding aimed at advancing its pipeline of potential cancer therapies. However, as a clinical-stage biotech company, significant revenue generation is generally contingent on the successful development, approval, and commercialization of its drug candidates.

IDEAYA Biosciences Financial Statement Overview

Summary

IDEAYA Biosciences faces significant financial challenges with declining revenues and consistent net losses. The company maintains a strong equity position, suggesting stability, but profitability and cash flow constraints pose risks. Strategic improvements are necessary for future growth.

Income Statement

The company has seen a significant decline in revenue over the past year, with a negative growth rate of 70%. Gross profit margin remains at 100% due to no cost of goods sold reported. However, high negative net profit, EBIT, and EBITDA margins reflect operational challenges and lack of profitability.

Balance Sheet

IDEAYA Biosciences maintains a strong equity base, with an equity ratio of 94%. The debt-to-equity ratio is low, indicating minimal leverage, but return on equity is negative due to net losses, highlighting profitability challenges.

Cash Flow

Operating cash flow and free cash flow are both negative, indicating cash burn from operations. However, the company has managed substantial financing activities, improving cash reserves significantly, albeit not enough to cover the free cash flow deficit.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	7.00M	7.00M	23.39M	50.93M	27.94M	19.54M
Gross Profit	5.26M	3.17M	19.38M	48.83M	26.22M	-20.16M
EBITDA	-357.95M	-326.98M	-130.42M	-60.40M	-48.54M	-33.96M
Net Income	-306.31M	-274.48M	-112.96M	-54.81M	-47.53M	-32.27M
Balance Sheet
Total Assets	1.10B	1.12B	649.32M	387.97M	381.35M	298.27M
Cash, Cash Equivalents and Short-Term Investments	692.51M	676.32M	525.11M	373.15M	368.06M	283.58M
Total Debt	25.97M	19.17M	2.87M	3.48M	5.18M	6.72M
Total Liabilities	76.51M	64.94M	28.23M	387.97M	381.35M	298.27M
Stockholders Equity	1.02B	1.06B	621.09M	349.45M	301.51M	198.27M
Cash Flow
Free Cash Flow	-267.98M	-251.44M	-117.59M	-90.62M	-58.42M	54.97M
Operating Cash Flow	-264.11M	-247.58M	-115.22M	-87.17M	-55.78M	55.46M
Investing Cash Flow	-68.77M	-502.56M	-158.46M	-33.40M	-69.67M	-146.24M
Financing Cash Flow	354.58M	677.55M	362.72M	97.17M	145.45M	128.75M

IDEAYA Biosciences Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 22.10
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IDYA, the sentiment is Positive. The current price of 22.1 is above the 20-day moving average (MA) of 21.82, above the 50-day MA of 20.22, and below the 200-day MA of 23.55, indicating a neutral trend. The MACD of 0.43 indicates Positive momentum. The RSI at 58.42 is Neutral, neither overbought nor oversold. The STOCH value of 51.37 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IDYA.

IDEAYA Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
KYMR	60 Neutral	$3.14B	―	-32.17%	―	-25.85%	-23.89%
IMCR	58 Neutral	$1.66B	―	-5.78%	―	25.50%	64.63%
CGON	58 Neutral	$2.05B	―	-16.57%	―	―	―
IDYA	53 Neutral	$1.94B	―	-31.34%	―	-54.85%	-79.25%
BEAM	52 Neutral	$2.01B	―	-38.04%	―	-82.38%	-164.76%
Sector *	46 Neutral	C$194.28M	-4.22	-8.60%	2.64%	13.54%	-1.44%
ETNB	42 Neutral	$1.48B	―	-69.30%	―	―	-68.13%

IDEAYA Biosciences Corporate Events

IDEAYA Biosciences Appoints New Chief Financial Officer

On June 26, 2025, IDEAYA Biosciences appointed Joshua Bleharski, Ph.D. as Chief Financial Officer and Principal Financial Officer. This strategic appointment may influence the company’s financial management and operational strategies.

The most recent analyst rating on (IDYA) stock is a Hold with a $27.00 price target. To see the full list of analyst forecasts on IDEAYA Biosciences stock, see the IDYA Stock Forecast page.

IDEAYA Biosciences Holds Annual Stockholders Meeting

On June 24, 2025, IDEAYA Biosciences held its Annual Meeting of Stockholders where three proposals were voted on. The election of two Class III directors, ratification of PricewaterhouseCoopers LLP as the independent auditor, and approval of executive compensation were addressed. The election saw Jeffrey L. Stein, Ph.D., and Scott W. Morrison nominated, with Stein receiving more votes. The ratification of the auditor was largely uncontested, and the executive compensation received a majority vote in favor, indicating shareholder support for the company’s leadership and financial oversight.

The most recent analyst rating on (IDYA) stock is a Hold with a $27.00 price target. To see the full list of analyst forecasts on IDEAYA Biosciences stock, see the IDYA Stock Forecast page.